Organic and Inorganic Nanoparticles for Prevention and Diagnosis of Gastric Cancer
Author
dc.contributor.author
Oyarzún Ampuero, Felipe
Author
dc.contributor.author
Guerrero Hernández, Ariel
Author
dc.contributor.author
Hassan López, Natalia
Author
dc.contributor.author
Morales Valenzuela, Javier
Author
dc.contributor.author
Bollo Dragnic, Soledad
Author
dc.contributor.author
Corvalán Rodríguez, Alejandro
Author
dc.contributor.author
Quest, Andrew F. G.
Author
dc.contributor.author
Kogan Bocian, Marcelo
Admission date
dc.date.accessioned
2015-12-23T01:26:33Z
Available date
dc.date.available
2015-12-23T01:26:33Z
Publication date
dc.date.issued
2015
Cita de ítem
dc.identifier.citation
Current Pharmaceutical Design Volumen: 21 Número: 29 (2015)
en_US
Identifier
dc.identifier.issn
1381-6128
Identifier
dc.identifier.other
DOI: 10.2174/1381612821666150901095538
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/135914
General note
dc.description
Artículo de publicación ISI
en_US
General note
dc.description
Sin acceso a texto completo
Abstract
dc.description.abstract
Organic and inorganic nanoparticles show great potential for cancer diagnosis and treatment. Because gastric cancer (GC) represents the second most deadly type of neoplasia worldwide, continued research efforts by scientists and clinicians are essential to improve diagnosis and treatment. This paper reviews significant findings in the area of nanoparticles (organic and inorganic origin) that may aid in prevention and diagnosis of GC. This review focuses in the first section on H. pylori and the connection to GC, highlighting nanoformulations designed to control bacterial growth. The second section evaluates the potential of different imaging techniques (especially using inorganic nanoparticles) in the detection of GC, and the third section summarizes how nanotechnology may be employed in the analytical detection of GC biomarkers (metallic plasmons, electrochemical biosensors and colorimetric sensors). We foresee that the prevention and diagnosis of GC will require the development of complex collaborative studies. Additionally, scientists also need to be tightly connected to industry in order to facilitate upscaling and rapid transfer of promising products to the clinic
en_US
Patrocinador
dc.description.sponsorship
Fondecyt
11121481
1130425
3150360
3140489
1111014
1130250
11130235
Ring grant 1111